Precision BioSciences (DTIL) to Release Quarterly Earnings on Tuesday

Precision BioSciences (NASDAQ:DTIL) is projected to announce its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.6550) per share and revenue of $4.05 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 9:30 AM ET.

Precision BioSciences Stock Performance

Shares of DTIL stock traded up $0.36 during trading hours on Monday, reaching $7.64. 63,782 shares of the company’s stock were exchanged, compared to its average volume of 256,002. The company has a market cap of $197.11 million, a P/E ratio of -1.49 and a beta of 1.31. The company’s 50 day moving average is $6.02 and its two-hundred day moving average is $5.36. Precision BioSciences has a 1 year low of $3.53 and a 1 year high of $8.82. The company has a debt-to-equity ratio of 0.24, a current ratio of 13.32 and a quick ratio of 13.32.

Insider Transactions at Precision BioSciences

In related news, CFO John Alexander Kelly sold 8,149 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total value of $31,292.16. Following the sale, the chief financial officer owned 125,883 shares in the company, valued at $483,390.72. This represents a 6.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael Amoroso sold 20,559 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total value of $78,946.56. Following the completion of the sale, the chief executive officer owned 243,392 shares in the company, valued at approximately $934,625.28. This represents a 7.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 33,633 shares of company stock valued at $129,151. 2.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in DTIL. Boothbay Fund Management LLC boosted its position in shares of Precision BioSciences by 497.1% in the 4th quarter. Boothbay Fund Management LLC now owns 1,066,050 shares of the company’s stock worth $4,435,000 after buying an additional 887,515 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in Precision BioSciences during the fourth quarter worth about $3,320,000. Bleichroeder LP raised its position in Precision BioSciences by 54.7% during the fourth quarter. Bleichroeder LP now owns 1,662,500 shares of the company’s stock worth $6,916,000 after acquiring an additional 587,500 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of Precision BioSciences in the fourth quarter valued at about $1,648,000. Finally, Renaissance Technologies LLC grew its position in shares of Precision BioSciences by 66.4% in the fourth quarter. Renaissance Technologies LLC now owns 326,477 shares of the company’s stock valued at $1,358,000 after purchasing an additional 130,300 shares during the last quarter. Institutional investors and hedge funds own 37.99% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. JonesTrading restated a “buy” rating and issued a $30.00 price target on shares of Precision BioSciences in a research note on Friday, April 17th. Wall Street Zen upgraded Precision BioSciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $19.00 target price on shares of Precision BioSciences in a report on Friday, March 13th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Precision BioSciences currently has an average rating of “Moderate Buy” and a consensus target price of $36.33.

About Precision BioSciences

Precision BioSciences is a clinical?stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno?oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin?out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.